Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Purchases of marketable securities | (161,737) | (7,708) |
| Maturities of marketable securities | 16,982 | 11,987 |
| Purchases of property and equipment | (91) | (36) |
| Net cash (used in) provided by investing activities | (144,846) | 4,243 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock in connection with follow-on public offering, net | 189,407 | — |
| Proceeds from exercise of common stock options | 1,339 | 279 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's capex?
- Corvus Pharmaceuticals (CRVS) reported capex of $91K in Q1 2026.
- How has Corvus Pharmaceuticals's capex changed year-over-year?
- Corvus Pharmaceuticals's capex increased by 152.8% year-over-year, from $36K to $91K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Corvus Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude